Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 22, Issue 7, Pages -Publisher
MDPI
DOI: 10.3390/ijms22073709
Keywords
NAD(+); NAMPT; NMN; NR; NMNH; aging; senescence; SBI-797812; PNGL; IRW
Funding
- JSPS KAKENHI [17K08569]
- Grants-in-Aid for Scientific Research [17K08569] Funding Source: KAKEN
Ask authors/readers for more resources
NAD(+) is a critical metabolite that has been shown to slow down aging processes and prevent age-related diseases by supplementing NAD(+) precursors. Human clinical trials have demonstrated its potential application in addressing age-associated physiological decline.
Aging is a phenomenon underlined by complex molecular and biochemical changes that occur over time. One of the metabolites that is gaining strong research interest is nicotinamide adenine dinucleotide, NAD(+), whose cellular level has been shown to decrease with age in various tissues of model animals and humans. Administration of NAD(+) precursors, nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR), to supplement NAD(+) production through the NAD(+) salvage pathway has been demonstrated to slow down aging processes in mice. Therefore, NAD(+) is a critical metabolite now understood to mitigate age-related tissue function decline and prevent age-related diseases in aging animals. In human clinical trials, administration of NAD(+) precursors to the elderly is being used to address systemic age-associated physiological decline. Among NAD(+) biosynthesis pathways in mammals, the NAD(+) salvage pathway is the dominant pathway in most of tissues, and NAMPT is the rate limiting enzyme of this pathway. However, only a few activators of NAMPT, which are supposed to increase NAD(+), have been developed so far. In this review, we will focus on the importance of NAD(+) and the possible application of an activator of NAMPT to promote successive aging.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available